<SEC-DOCUMENT>0001104659-24-114778.txt : 20241106
<SEC-HEADER>0001104659-24-114778.hdr.sgml : 20241106
<ACCEPTANCE-DATETIME>20241106160147
ACCESSION NUMBER:		0001104659-24-114778
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20241106
DATE AS OF CHANGE:		20241106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Transcode Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001829635
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811065054
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40363
		FILM NUMBER:		241430792

	BUSINESS ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		857-301-6857

	MAIL ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2427567d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Rule&nbsp;14a-101)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Information Required in Proxy Statement<BR>
Schedule 14A Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the<BR>
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Filed by the Registrant </FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Filed by a Party other than the Registrant
</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box: <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preliminary Proxy Statement <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>
Definitive Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#120;</FONT> Definitive Additional
Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Soliciting
Material Pursuant to &sect;240.14a-12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Person(s)&nbsp;Filing Proxy Statement, if other than the Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT>
No fee required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>
Fee paid previously with preliminary materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT> Fee computed
on table in exhibit required by Item 25(b)&nbsp;per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and 0-11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2427567d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">BOSTON, November 5, 2024 - TransCode
Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today
announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode
appeared on October 1, 2024, has determined to grant TransCode&rsquo;s request to continue its listing on The Nasdaq Stock Market subject
to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">The listing standards of issue
included the bid price requirement in Nasdaq Listing Rule 5550(a)(2); the equity requirement in Listing Rule 5550(b); and Listing Rule
5635(d), concerning shareholder approval of transactions other than public offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A"><B>About TransCode Therapeutics</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">TransCode is a clinical-stage
oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and
effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company&rsquo;s lead therapeutic candidate,
TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.
In addition, TransCode is developing a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges
of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety
of cancers.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A"><B>Forward-Looking Statements</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">This release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements
concerning the continued listing of TransCode Therapeutics&rsquo; stock on The Nasdaq Stock Market. Any forward-looking statements in
this press release are based on management&rsquo;s current expectations of future events and are subject to a number of risks and uncertainties
that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that
the results of clinical trials will not be consistent with TransCode&rsquo;s pre-clinical studies or expectations or with results from
previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode&rsquo;s financial condition
and its need to obtain additional funding to support its business activities, including TransCode&rsquo;s ability to continue as a going
concern; risks associated with the timing and outcome of TransCode&rsquo;s planned regulatory submissions; risks associated with obtaining,
maintaining and protecting intellectual property; risks associated with TransCode&rsquo;s ability to enforce its patents against infringers
and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for
similar uses; risks associated with TransCode&rsquo;s dependence on third parties; and risks associated with geopolitical events and pandemics,
including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important
factors, any of which could cause TransCode&rsquo;s actual results to differ from those contained in or implied by the forward-looking
statements, see the section entitled &ldquo;Risk Factors&rdquo; in TransCode&rsquo;s Annual Report on Form 10-K for the year ended December
31, 2023, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with
the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode undertakes
no duty to update this information unless required by law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #0A0A0A"><IMG SRC="tm2427567d1ex99-1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0A0A0A"><B>For more information,
please contact:</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #0A0A0A; margin: 0pt 0">TransCode Therapeutics, Inc.&nbsp;<BR>
Tania Montgomery-Hammon, VP of Business Development&nbsp;<BR>
tania.montgomery@transcodetherapeutics.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2427567d1ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2427567d1ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( ;@# 2(  A$! Q$!_\0
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M$HCDRQ>9V)^; _K.T3]BS]C>31-+DE_9,_9IXTO3@!_PHKX8C'[F-PH'_",
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M[+O=.M_!B_"Q-;3(7<?$OB35O-7Y<XCW%2 0/1?%OQ8_X*K?M:Z5J/@+P?\
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M%3Q=]9RE)KU?IVT^5SV,-AOJN%CA$U[J=OP?^7H?F#_P5WY_8A^(61C&O^
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MA[JGB/6/ O@?6?&.EIH'B_4O"7AC5_%OA^(*!H_B/6=%AFUS2$(.=MMKCSQ
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MQVG) ^;<#5ZU@BL[:"WBSY-O;K;()3SL7:,L2 #TP>,<@ $"OR<^&'P>TO\
M9\\8_"*P^*'@O0_%5QK7QJ\6:O\ #/\ :K^&VL21^)?%?B?XJ3^.];T;PK\9
MM,:%O$IT'7_#>M3>&X_+\5^,_!,LFA>$5F>VS')&4**Q"N^S:3>]DV]VKZ*[
MUO:[2=F@K5N31?-[[_U]Y^HTWC#PM#JQ\.2^*- @UX+8!=(;5M.&KJ=7D*:0
M!I3.9W\\C,!1<2JHD4,C!AMP7UE??:%M+J"X-M<M:7?V><,UI>K@-&P'1P7
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M)/"Q\1"YN2;%#X.T9M$T<:5#M'D[HF+2EF/FR,7(0[5;(^+GPG\+?&GP;=^
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5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2427567d1ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2427567d1ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !? &4# 2(  A$! Q$!_\0
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MHKE=-\3>'=>N]8M-"UO1=9U#PQ??V3X@M-*U73+[4-$U(HTC:1K<,+R/I$Y
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M::_:$^*WQAL;WPMX4T#XT7>K_!6?X8VY^$WQ:\6GQ-\-/A_K6O\ C77OVC_
M#^%/CD_AJV\2:UK?AWPE\,_"?B_PEX0A\4>'_%<WCL>."W@R/PCE? ']ESXN
M3_%6^\!_M(I\1?#]A\#/"FJ6_P &/B9^SYXQ\8^!?AQ\:-*^*FLMK_QT^)WC
MG7-$\1I\2_#_ .T+\5?B,P\5>-O"TTL,?@Z.4-\//'?C:2;Q9XOG_9A(A%$J
M#!V]_;/3\S7H5ZZRUMX25^:*3Y;;7;34K;23V:=KRBT]3GNL2M=$G?OOIMU,
MNRTVSM([,11"XFM+06EK?76;S46L@>$.JMNDP^=VTR$,<'DG=6W117GG0%%%
M% 'C_B+P_K]EXO'C+PG;:/J$][X<T[P[X@T?7=0DT=+W3]"U?5=5\/:I9ZS%
MH'B*9IO#\GB/7REH(S;RKJQ,AAG2#/*Z1J<?PP\.R1>,+J$:_P"(/%?B'Q#:
M>%O"-CJVN:JPUO6I-8&FZ+I4,$FN>(C#!(][XLUL6@C,[:Y*1;P.K1_0Y? !
M'?\ I^5>!>+?#5UH'BA_B[X<\.W/B#Q/'X>;PGXAT#3UT^'5-<\+Q:Y%J\4N
MBG5I3&=;\..9)@JW$0\6PYMYE\VW\,&#JPS32P^B7=NU[7M%R>B5V]?2^FJ\
M_$4%=XOJOPNK7\^GZ:GL&@ZYI7B/2;#7=#O;?4])U.U%Y97=J04NT8'YDXQ@
MD;2#R&X)Q@GH*\2^$T6MMIGB74]:\/W'@Z'Q'XPU3Q%H7A35)M*.I:+IVK1:
M0VL_VB^CO+ 9_$OBM-?\42_O)Y$?7?+N) Z**]MK&NK-KR?]>?KY&^'V^7^0
M4445F=(AY!'J#7YU_%B+XU^(_P!K?PSXB^%'P\^'/CVT_9Z^"NJO?6GQ*\:>
M+_AIIFH^*?VA/$2)+/X,\1>'?AS\5P_B'P?X<^"">?!)X457M/BN8!XLC GM
M1^BM)@'J ?PJZ-;ZOJK/W7'6Z5FK/;79M)W5KWOT8<=X3U+7-7\.:-JGB7PO
M=>#-?N[(7FJ^%)]9TS5I-#U"0;6THZSH3-H.L;"-JS1S,ARKGGA.RHHJ /R#
M_;Y_;1_;R_9L^*'A+PK^RM_P3O\ %/[8'@?7/ D?B7Q'XUT'QNWAB'0/%+:W
MKVDMX-$8\->)XRXT72M'\0%VB5F&LK&0"&W?#O\ P]C_ ."QX_YP=^/!_P!U
M6U<?^\VK^EK#8Y('^]C_  -)F/'S;<^NW'^?T^E=5#$X:,4GE=*5MY2<XWW_
M )6E\EV/.KX?%.[69RCY*,/U3/YI!_P5C_X+&?P_\$.O'7KQ\6-8/_O-S[<T
M_P#X>Q_\%D?^D'?C[_PZVK__ #M:_3']A#XA>.?'GBCX]6_C?Q;J_B2#P_K'
MAJ+1+75KM;\Z9%-K'CV)TB=5R@8Z)#\J@!MJ\$JN/TG ;G<%QWRHZ>GO^&,U
MZ&8_5LLQ<\%+*:+G!I2LZR2;2E;WI)[-?*S/.RYXK,\)'%QS25I7M:,+*W>R
ML>'_ +.WCKXD?%/X'_#'XA_%[X8W7P6^)OC'P?IFM>.?A3>WRZCJ'@;Q)-D3
M:%+JL>Q)C#M!!*?=D4 EO-9_=:**\4^B/@KQ$/$VF^+KO5=5\:^/==U:S\9>
M+;;0?#ECJL6E^&[3Q-X0&C_%SP9X(T;1/#T?A-M>;QE\(3K6@3/XH?Q:\EQ&
M7>1OWBR?>F.,'T _*LZ"QLH9;B:VM8+>:YG6XNYUME#7;8P69_O%\ <DD@@D
M+\Q-:5:UZZQ*6R25M$K;+9*VFGG?>]SFP^&6&35_^!U_KML%%%%9'2%<=<:!
MJ\L\TD?C;Q3#%, JVUM:^$"MF=N<JTOAN63K_>:1B>K-UKL:* *%O"UO;PP2
MS374MM;A3<W&T&Z;;\S28X+$@$C&5R.6Y)OUYGX$^*G@3XFS>+X/!/B+3]=N
M/ OB?4_!OB2VM;A)#IWB/1G7S;9]K$  '.\95@.X3)],H **** /R@_X)P_\
MCK^TGGI_;OA;/_@V^(-?JSN4DC'J??GZY]NGTZ&O@_\ 8^^ 'Q ^#'B/XQ:M
MXW@T6"V\>7_AN[TE=*U5]1(71+[Q++ME#A6C!375/S '.%(SD#[NPJ@N<YSC
M [XQ_B.F/\/4XAQ.%Q6=59X25X-Q=/EZ15-*3=^\D_3SN>)P_AYX3*:<<5H_
M>O?U_P"&+%%%9US=06=M->WTL-M;VUNUU<W%P5"V@"Y9B3@!%"MWSD8&<@5Y
M9[9SE[HFJ7$T]S#XT\2Z9"RA3:VEIX1:RLPH'(_MCPS<2LN,<EV(_B]3O6L,
MMI8P07-Y=WTJC:]U<B,7MR%!.X_V5'&G0GE(\ =1TKB]"CO]:\0S^,+3Q+;Z
MKX(U?PYI:>%=,T^X2_TR],DD>K#Q6)5(1I)MZ00F)G#QA6#DF/?Z55MVM_73
MT^_]6 4445 !7-^(?#^D^*="U;P]KEJ+K2M<LY-)U.W:5[7[382!ED *$,H*
MNPPI4LI(SMP*Z2B@#XZE^*?@KX8?$ZP\&V_@:3X:^!-&\(Z1X/L_'-UX1U/P
MWX9\0:OX?-Q;>!_@/\+M#M]!0>)3H-CKFM^)+=?#3K;1,L7A#P)9^+;F/QK'
MX(^Q:Y/4O#VA76KZ/XAO=#L+_P 0^'(=4;0+V4(=1L?[81%UI=+9U9@9XDB1
M\#) " INRWR_\+-<^)WAOP]\1OB_\;O$5]H6@M:^)_$WB'P)<:)K>ICP(WAN
M1IC!X1E*2R0Q^%]!@N?!UX/#B>+?"'QGD\/>'OC9X%/@FY\:>+/!<NEEB-O3
MJW)MZ6W=_P -?.X'V917EW@_QQX?\>Z;?WV@/,\NCZ^WASQ+I&IVW]G:[X4\
M0K':ZTVBZ_HP>.71_$/V?6-&O#%(&+VNKZ%XC5Y+62,R>HUF 445$T@C ,A
M]QT_I_+T[T 2U\\^//%O@SQ'K_B_X$ZU)>%[_P"$U]XB^)NJ6=[IFG:=X'\
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F<?;;!=: BUCRCC:JRH$5E <87: I^]T=%%9@%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
